Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.

Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...

I am a 75-year-old woman who isn’t prediabetic or diabetic. My BMI is 31.2. My doctor has prescribed a trial of metformin for ...

I am a 75-year-old woman who isn’t prediabetic or diabetic. My BMI is 31.2. My doctor has prescribed a trial of metformin for ...

In light of recent revelations surrounding a new intranasal COVID-19 vaccine candidate, there is growing concern that the American public is once again being led into potentially dangerous territory ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

This is what it looks like when disinformation doctors pretend to value data and science to further their true objective, ...

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

The mass layoffs of federal employees have been unprecedented, devastating, and chaotic but it is the cuts to HHS that are ...

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...